Literature DB >> 9032108

Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.

T Hansen1, C B Andersen, S M Echwald, S A Urhammer, J O Clausen, H Vestergaard, D Owens, L Hansen, O Pedersen.   

Abstract

Phosphatidylinositol 3-kinase (PI3-K) may regulate the basal plasma membrane glucose transporter recycling and the organization of the transporter intracellular pool in addition to being an insulin signal for translocation of glucose transporters to the plasma membrane. The objectives of the present study were to examine for genetic variability in the human regulatory p85alpha subunit of PI3-K, to look for an association between gene variants and NIDDM in a case-control study, and to relate identified variability to potential changes in whole-body insulin sensitivity and glucose turnover in a phenotype study. Single-strand conformational polymorphism and heteroduplex analysis of the coding region of the regulatory p85alpha subunit in cDNA isolated from human muscle tissue from 70 insulin-resistant NIDDM patients and 12 control subjects revealed three silent polymorphisms and a missense mutation at nucleotide position 1020 (G-->A), changing a Met to Ile at codon 326. Using allele-specific oligohybridization, we found a similar allelic frequency of the codon 326Met-->Ile variant in 404 NIDDM patients (0.15 [95% CI 0.13-0.17]) and 224 matched glucose tolerant control subjects (0.16 [0.13-0.19]). In a random sample of 380 unrelated healthy young Caucasians aged 18-32 years, in whom we have performed a tolbutamide modified intravenous glucose tolerance test, we identified 263 wildtype subjects, 109 heterozygous subjects, and 8 subjects homozygous for the codon 326 variant (allelic frequency = 0.16 [0.13-0.19]). No difference in glucose disappearance constant (KG), insulin sensitivity index (SI), and glucose effectiveness (SG) was observed between wildtype and heterozygous subjects. However, compared with the combined values for wildtype and heterozygous carriers, KG was reduced by 40% (P = 0.004) and SG by 23% (P = 0.03) in homozygous carriers of the p85alpha variant. Moreover, in homozygous carriers, a 32% reduction was found in SI (P = 0.08). In conclusion, a codon 326Met-->Ile variant in the gene encoding the PI3-K p85alpha regulatory subunit is found in 31% of a random sample of young healthy Caucasians. About 2% of the subjects in this population carry the gene variant in its homozygous form, and these carriers are characterized by significant reductions in whole-body glucose effectiveness and intravenous glucose disappearance constant. In itself, the gene variant does not confer an increased risk of diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032108     DOI: 10.2337/diab.46.3.494

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

Review 1.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

2.  Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85alpha.

Authors:  Katrine Almind; Laurent Delahaye; Torben Hansen; Emmanuel Van Obberghen; Oluf Pedersen; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

3.  Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.

Authors:  Y Jamshidi; H Snieder; X Wang; M J Pavitt; T D Spector; N D Carter; S D O'Dell
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

4.  Evidence of an association between genetic variation of the coactivator PGC-1beta and obesity.

Authors:  G Andersen; L Wegner; K Yanagisawa; C S Rose; J Lin; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; T Hansen; B M Spiegelman; O Pedersen
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

5.  Genomewide search for type 2 diabetes susceptibility genes in four American populations.

Authors:  M G Ehm; M C Karnoub; H Sakul; K Gottschalk; D C Holt; J L Weber; D Vaske; D Briley; L Briley; J Kopf; P McMillen; Q Nguyen; M Reisman; E H Lai; G Joslyn; N S Shepherd; C Bell; M J Wagner; D K Burns
Journal:  Am J Hum Genet       Date:  2000-05-02       Impact factor: 11.025

6.  Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.

Authors:  Eva-Maria D Nielsen; Lars Hansen; Trine Stissing; Keiko Yanagisawa; Knut Borch-Johnsen; Pernille Poulsen; Allan Vaag; Torben Hansen; Oluf Pedersen
Journal:  J Mol Med (Berl)       Date:  2005-04-09       Impact factor: 4.599

7.  Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.

Authors:  O Laukkanen; J Pihlajamäki; J Lindström; J Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; J Tuomilehto; M Uusitupa; M Laakso
Journal:  Diabetologia       Date:  2004-05-01       Impact factor: 10.122

Review 8.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.

Authors:  P R Shepherd; D J Withers; K Siddle
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

9.  PI3K Pathway in NSCLC.

Authors:  Alex Martinez-Martí; Enriqueta Felip
Journal:  Front Oncol       Date:  2012-01-06       Impact factor: 6.244

10.  Impact of rs361072 in the phosphoinositide 3-kinase p110beta gene on whole-body glucose metabolism and subunit protein expression in skeletal muscle.

Authors:  Rasmus Ribel-Madsen; Pernille Poulsen; Johan Holmkvist; Brynjulf Mortensen; Niels Grarup; Martin Friedrichsen; Torben Jørgensen; Torsten Lauritzen; Jørgen F P Wojtaszewski; Oluf Pedersen; Torben Hansen; Allan Vaag
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.